Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: Is it helpful to policy makers?

C. L. Bennett*, P. O. Weinberg, R. M. Golub

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: Is it helpful to policy makers?'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science